Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

AnaptysBio stock price, quote, forecast and news

ANAB
US0327241065
A2AJ8C

Price

37.75
Today +/-
+0.41
Today %
+1.23 %
P

AnaptysBio stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the AnaptysBio stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the AnaptysBio stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the AnaptysBio stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze AnaptysBio's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

AnaptysBio Stock Price History

DateAnaptysBio Price
8/23/202437.75 undefined
8/22/202437.29 undefined
8/21/202437.78 undefined
8/20/202436.05 undefined
8/19/202436.45 undefined
8/16/202434.00 undefined
8/15/202432.45 undefined
8/14/202434.65 undefined
8/13/202433.33 undefined
8/12/202433.75 undefined
8/9/202433.05 undefined
8/8/202433.59 undefined
8/7/202431.54 undefined
8/6/202432.08 undefined
8/5/202432.37 undefined
8/2/202432.76 undefined
8/1/202434.08 undefined
7/31/202434.84 undefined
7/30/202434.74 undefined
7/29/202437.00 undefined

AnaptysBio Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into AnaptysBio, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by AnaptysBio from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects AnaptysBio’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of AnaptysBio. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into AnaptysBio’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing AnaptysBio’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on AnaptysBio’s growth potential.

AnaptysBio Revenue, EBIT and net profit per share

DateAnaptysBio RevenueAnaptysBio EBITAnaptysBio Net Income
2029e207.35 M undefined0 undefined-75.38 M undefined
2028e90.98 M undefined-323.71 M undefined-179.74 M undefined
2027e27.11 M undefined-288.87 M undefined-194.93 M undefined
2026e36.51 M undefined-260.09 M undefined-193.15 M undefined
2025e29.52 M undefined-218.92 M undefined-191.66 M undefined
2024e32.73 M undefined-165.82 M undefined-186.82 M undefined
202317.16 M undefined-157.07 M undefined-163.62 M undefined
202210.29 M undefined-115.15 M undefined-128.72 M undefined
202163.18 M undefined-56.81 M undefined-57.8 M undefined
202075 M undefined-23.88 M undefined-19.93 M undefined
20198 M undefined-107.43 M undefined-97.34 M undefined
20185 M undefined-66.72 M undefined-61.66 M undefined
201710 M undefined-28.78 M undefined-30.07 M undefined
201616.68 M undefined-3.03 M undefined-4.26 M undefined
201517.57 M undefined-3.32 M undefined-5.41 M undefined
201415.84 M undefined4.87 M undefined230,000 undefined
20135.48 M undefined-5.29 M undefined-5.55 M undefined

AnaptysBio Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
51517161058756310173229362790207
-200.0013.33-5.88-37.50-50.0060.00837.50-16.00-84.1370.0088.24-9.3824.14-25.00233.33130.00
-----------------
00000000000000000
-54-3-3-28-66-107-23-56-115-157-165-218-260-288-3230
-100.0026.67-17.65-18.75-280.00-1,320.00-1,337.50-30.67-88.89-1,150.00-923.53-515.63-751.72-722.22-1,066.67-358.89-
-50-5-4-30-61-97-19-57-128-163-186-191-193-194-179-75
----20.00650.00103.3359.02-80.41200.00124.5627.3414.112.691.050.52-7.73-58.10
19.1619.1619.1620.1719.7824.6727.0627.327.4328.1726.92000000
-----------------
Details

Keystats

ⓘ

Revenue and Growth

The AnaptysBio Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the AnaptysBio is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20132014201520162017201820192020202120222023
2.822.251.751.2248.4427.1374.2393.7548.1441.2390.9
00000000000
00000000000
00000000000
0.20.80.61.62.773.52.94.94.59.08
32352.352.8251.1434.1377.7396.6553445.7399.98
0.80.60.60.50.71.432.121.82018.27
000075.973.154.317.567.1142.927.03
00000000000
00000000000
00000000000
0.10.12.33.50.10.20.10.30.30.30.26
0.90.72.9476.774.757.419.989.2163.245.55
3.923.755.256.8327.8508.8435.1416.5642.2608.9445.54
34.736.877.577.50000000.03
14.214.415.516.7393633.3648.7660.7678.6717.8702.97
-48.8-45.3-50.7-54.9-85-146.7-244-264-321.8-450.5-614.1
0000-400-2003000-400-5,200-797
00000000000
0.15.942.339.3307.6486.4405396.7356.4262.188.1
0.20.41.52.32.35.416.24.21.72.84.7
0.71.12.83.44.98.811.915.614.423.332.74
1.410.23.1000.100000
8000000000000
00006.97.61.40000
3.111.77.45.714.121.929.519.816.126.137.44
04.84.913.87.60.600000
00000000000
0.62.61.73.40.10.20.70270.5322.2326.84
0.67.46.617.27.70.80.70270.5322.2326.84
3.719.11422.921.822.730.219.8286.6348.3364.29
3.82556.362.2329.4509.1435.2416.5643610.4452.39
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of AnaptysBio provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand AnaptysBio's financial health and stability.

Assets

AnaptysBio's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that AnaptysBio must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of AnaptysBio after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into AnaptysBio's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20132014201520162017201820192020202120222023
-53-5-4-30-61-97-19-57-128-163
00000000000
00000000000
-19-6-74316-6-760
012310192223347475
00001,0001,00000000
00000000000
-514-9-9-19-48-69-14-45-73-120
00000-100-100
0000-243-1421319438-394144
0000-242-1411329540-394145
00000000000
140100-6-7-1000
0040029423030211-47
14398292223-4025244-59
00-1-1-100024932-11
00000000000
-31929029325779245-424-35
-5.8414.45-9.91-9.08-19.73-49.57-70.33-14.73-47.29-73.95-121.61
00000000000

AnaptysBio stock margins

The AnaptysBio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AnaptysBio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AnaptysBio.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the AnaptysBio's sales revenue. A higher gross margin percentage indicates that the AnaptysBio retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the AnaptysBio's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the AnaptysBio's total revenue generated. When comparing the revenue margin year over year, investors can gauge the AnaptysBio's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the AnaptysBio. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the AnaptysBio's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

AnaptysBio Margin History

AnaptysBio Gross marginAnaptysBio Profit marginAnaptysBio EBIT marginAnaptysBio Profit margin
2029e0 %0 %-36.35 %
2028e0 %-355.8 %-197.56 %
2027e0 %-1,065.54 %-719.02 %
2026e0 %-712.43 %-529.08 %
2025e0 %-741.48 %-649.17 %
2024e0 %-506.58 %-570.73 %
20230 %-915.5 %-953.66 %
20220 %-1,119.05 %-1,250.92 %
20210 %-89.92 %-91.48 %
20200 %-31.84 %-26.57 %
20190 %-1,342.88 %-1,216.75 %
20180 %-1,334.4 %-1,233.2 %
20170 %-287.8 %-300.7 %
20160 %-18.17 %-25.54 %
20150 %-18.9 %-30.79 %
20140 %30.74 %1.45 %
20130 %-96.53 %-101.28 %

AnaptysBio Stock Sales Revenue, EBIT, Earnings per Share

The AnaptysBio earnings per share therefore indicates how much revenue AnaptysBio has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue AnaptysBio earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates AnaptysBio's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of AnaptysBio’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating AnaptysBio's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

AnaptysBio Revenue, EBIT and net profit per share

DateAnaptysBio Sales per ShareAnaptysBio EBIT per shareAnaptysBio Earnings per Share
2029e7.59 undefined0 undefined-2.76 undefined
2028e3.33 undefined0 undefined-6.58 undefined
2027e0.99 undefined0 undefined-7.13 undefined
2026e1.34 undefined0 undefined-7.07 undefined
2025e1.08 undefined0 undefined-7.02 undefined
2024e1.2 undefined0 undefined-6.84 undefined
20230.64 undefined-5.83 undefined-6.08 undefined
20220.37 undefined-4.09 undefined-4.57 undefined
20212.3 undefined-2.07 undefined-2.11 undefined
20202.75 undefined-0.87 undefined-0.73 undefined
20190.3 undefined-3.97 undefined-3.6 undefined
20180.2 undefined-2.7 undefined-2.5 undefined
20170.51 undefined-1.46 undefined-1.52 undefined
20160.83 undefined-0.15 undefined-0.21 undefined
20150.92 undefined-0.17 undefined-0.28 undefined
20140.83 undefined0.25 undefined0.01 undefined
20130.29 undefined-0.28 undefined-0.29 undefined

AnaptysBio business model

AnaptysBio Inc is a biopharmaceutical company founded in 2005 and headquartered in San Diego, California. The company focuses on researching, developing, and marketing novel therapeutic antibodies for the treatment of autoimmune diseases, inflammation, and cancer. AnaptysBio has a unique business model that aims to make antibody development more efficient and cost-effective. Instead of relying on traditional methods like the hybridoma technique, the company uses its proprietary SHM-XEL technology to isolate and identify human antibodies directly from B cells. This approach allows AnaptysBio to quickly find, test, and optimize high-quality antibody candidates, resulting in significantly shorter development times and lower costs. The company has two main divisions. The first division focuses on the development of antibodies for the treatment of autoimmune diseases and inflammation. In this division, AnaptysBio has several promising antibody candidates in its pipeline, including ANB020, an antibody against the immune system protein IL-33, being developed for the treatment of asthma and other allergic diseases. ANB019, an antibody against the immune system protein IL-36R, being developed for the treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis, is another promising candidate. The second division of AnaptysBio focuses on the development of antibodies for the treatment of cancer. Here, the company has formed a promising partnership with TESARO, a leading cancer therapy company. Together, they are developing an antibody called TSR-042 that targets the immune system protein PD-1 and is used for the treatment of various cancers such as lung cancer and bladder cancer. AnaptysBio also has several products on the market that are based on its proprietary SHM-XEL technology. These include Simponi (Golimumab), an antibody used for rheumatoid arthritis, Crohn's disease, and psoriasis, for which AnaptysBio developed the technology in partnership with Janssen Biotech. Over the years, AnaptysBio has received several significant awards and recognition for its innovative antibody development platforms and technologies. In 2017, the company was included in the Deloitte Technology Fast 500 list and received the Frost & Sullivan Technology Innovation Award for its SHM-XEL technology. Overall, AnaptysBio is an innovative biopharmaceutical company with a unique business model and a promising pipeline of antibody candidates for the treatment of autoimmune diseases, inflammation, and cancer. Through its proprietary technology and partnerships with other companies, AnaptysBio remains well-positioned to continue providing innovative therapeutic solutions for patients. AnaptysBio is one of the most popular companies on Eulerpool.com.

AnaptysBio SWOT Analysis

Strengths

AnaptysBio Inc possesses several strengths that contribute to its success in the biotechnology industry. Firstly, the company has a strong and experienced management team with expertise in drug discovery and development. This enables them to make informed decisions and effectively navigate the complex regulatory landscape.

Secondly, AnaptysBio Inc boasts a robust portfolio of proprietary antibody therapeutics, which have shown promising results in preclinical and clinical trials. These innovative products have the potential to address unmet medical needs and generate significant revenue for the company.

Additionally, the company's strong financial position and access to capital provide them with the resources to further advance their research and development activities, and forge strategic partnerships with other industry leaders. This financial stability enables AnaptysBio Inc to pursue long-term growth and remain at the forefront of scientific advancements.

Weaknesses

Despite its strengths, AnaptysBio Inc also faces certain weaknesses that may hinder its performance. One notable weakness is its dependence on a limited number of proprietary antibody programs. This concentration of resources increases the company's vulnerability to setbacks, such as failed clinical trials or patent disputes.

Additionally, AnaptysBio Inc operates in a highly competitive industry, competing against larger pharmaceutical companies with substantial resources and established market presence. This competitive landscape puts pressure on the company to differentiate itself and successfully commercialize its products.

Opportunities

AnaptysBio Inc has several opportunities to capitalize on in the biotechnology sector. One major opportunity lies in the increasing demand for innovative antibody-based therapies. The growing prevalence of chronic diseases and the need for personalized medicine create a favorable market environment for AnaptysBio Inc to introduce and market their products.

Furthermore, the company can explore collaborations and licensing agreements with larger pharmaceutical companies to gain access to their established distribution networks and accelerate the commercialization of their products. This strategic approach can help penetrate new markets and broaden their revenue streams.

Threats

AnaptysBio Inc faces various threats that could impact its future prospects. One significant threat is the risk of regulatory hurdles and delays in obtaining necessary approvals for their drug candidates. The stringent regulatory requirements in the biopharmaceutical industry can prolong the time to market and increase costs.

Moreover, intellectual property disputes and patent challenges pose a threat to AnaptysBio Inc's market exclusivity and competitive advantage. Rival companies may challenge their patents, leading to lengthy legal battles that drain resources and potentially limit their market share.

AnaptysBio Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

AnaptysBio historical P/E ratio, EBIT, and P/S ratio.

AnaptysBio shares outstanding

The number of shares was AnaptysBio in 2023 — This indicates how many shares 26.924 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue AnaptysBio earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates AnaptysBio's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of AnaptysBio’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating AnaptysBio's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for AnaptysBio.

AnaptysBio latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-1.01 -1.71  (-69.51 %)2024 Q2
3/31/2024-1.6 -1.64  (-2.69 %)2024 Q1
12/31/2023-1.63 -1.59  (2.65 %)2023 Q4
9/30/2023-1.83 -1.41  (22.95 %)2023 Q3
6/30/2023-1.73 -1.5  (13.36 %)2023 Q2
3/31/2023-1.07 -1.58  (-47.8 %)2023 Q1
12/31/2022-0.98 -0.93  (4.74 %)2022 Q4
9/30/2022-0.74 -1.18  (-59.93 %)2022 Q3
6/30/2022-1.04 -1.15  (-10.35 %)2022 Q2
3/31/2022-1.01 -1.31  (-29.08 %)2022 Q1
1
2
3
4

Eulerpool ESG Scorecard© for the AnaptysBio stock

Eulerpool World ESG Rating (EESG©)

40/ 100

🌱 Environment

44

👫 Social

40

🏛️ Governance

37

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

AnaptysBio list of shareholders

%
Name
Stocks
Change
Date
7.46 % Deep Track Capital LP2,036,990676,81412/31/2023
7.14 % Tang Capital Management, LLC1,950,609012/31/2023
5.72 % BlackRock Institutional Trust Company, N.A.1,561,78212,83412/31/2023
5.04 % The Vanguard Group, Inc.1,377,513-322,66612/31/2023
4.76 % Boxer Capital, L.L.C.1,300,000012/31/2023
4.53 % First Light Asset Management, LLC1,237,178446,37212/31/2023
4.37 % Woodline Partners LP1,194,974354,15312/31/2023
3.58 % Great Point Partners, LLC976,98182,64812/31/2023
3.29 % Frazier Healthcare Partners899,700012/31/2023
27.53 % EcoR1 Capital, LLC7,521,024012/31/2023
1
2
3
4
5
...
10

AnaptysBio Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Bristol-Myers Squibb Stock
Bristol-Myers Squibb
SupplierCustomer-0,21-0,49-0,86-0,88-0,67-0,08
GlaxoSmithKline Stock
GlaxoSmithKline
SupplierCustomer-0,250,35-0,86-0,67-0,030,10
Merck Stock
Merck
SupplierCustomer-0,520,480,270,720,660,70
Power Stock
Power
SupplierCustomer-0,580,770,610,870,590,63
1

Most common questions regarding AnaptysBio

What values and corporate philosophy does AnaptysBio represent?

AnaptysBio Inc represents a commitment to scientific innovation and excellence in the field of biotechnology. Its core values include a focus on discovering and developing novel antibody therapeutics to address unmet medical needs. The company strives to create value for patients, healthcare professionals, and shareholders through its cutting-edge research and development efforts. With a corporate philosophy centered around collaboration, AnaptysBio Inc aims to leverage its expertise and partnerships to drive forward breakthrough therapies that have the potential to improve patients' lives and revolutionize healthcare.

In which countries and regions is AnaptysBio primarily present?

AnaptysBio Inc is primarily present in the United States.

What significant milestones has the company AnaptysBio achieved?

AnaptysBio Inc has achieved several significant milestones. The company has successfully developed novel antibody therapeutics for various severe diseases, including atopic dermatitis and peanut allergies. Additionally, AnaptysBio Inc has also entered into strategic collaborations with renowned pharmaceutical companies to further advance its drug pipeline. The company's dedication to research and development has led to the successful completion of multiple clinical trials, demonstrating their commitment to improving patient outcomes. With their innovative approach and strong partnerships, AnaptysBio Inc continues to pave the way in the field of biotechnology.

What is the history and background of the company AnaptysBio?

AnaptysBio Inc is a biotechnology company based in San Diego, California. Established in 2005, the company specializes in the discovery and development of therapeutic antibodies to address unmet medical needs. With a focus on inflammation, immuno-oncology, and rare diseases, AnaptysBio Inc utilizes its proprietary antibody discovery platform to identify and develop potential treatments. The company has forged collaborations with leading pharmaceutical companies and has a diverse pipeline of antibody candidates. AnaptysBio Inc's commitment to innovation and expertise in antibody-based therapies has positioned them as a prominent player in the biotech industry.

Who are the main competitors of AnaptysBio in the market?

The main competitors of AnaptysBio Inc in the market are Regeneron Pharmaceuticals, Inc., Amgen Inc., and Novartis AG.

In which industries is AnaptysBio primarily active?

AnaptysBio Inc is primarily active in the biotechnology industry.

What is the business model of AnaptysBio?

The business model of AnaptysBio Inc is focused on discovering and developing novel antibody-based therapeutics for inflammation and immuno-oncology. With a strong emphasis on research and development, AnaptysBio utilizes its proprietary technology platform to generate highly specific therapeutic antibodies. These antibodies are aimed at targeting and modulating key immune system pathways to address various diseases, including inflammatory disorders, severe allergies, and certain types of cancers. By leveraging its expertise in antibody engineering and design, AnaptysBio aims to deliver innovative treatments that can improve patient outcomes and provide value to healthcare providers.

What is the P/E ratio of AnaptysBio 2024?

The AnaptysBio P/E ratio is -5.44.

What is the P/S ratio of AnaptysBio 2024?

The AnaptysBio P/S ratio is 31.05.

What is the AlleAktien quality score of AnaptysBio?

The AlleAktien quality score for AnaptysBio is 5/10.

What is the revenue of AnaptysBio 2024?

The expected AnaptysBio revenue is 32.73 M USD.

How high is the profit of AnaptysBio 2024?

The expected AnaptysBio profit is -186.82 M USD.

What is the business model of AnaptysBio

AnaptysBio Inc is an innovative biotechnology company that focuses on the discovery and development of new biological therapeutics. The company was founded in 2005 in San Diego, California, and has since gained a leading position in the industry. The business model of AnaptysBio is based on the development of highly effective antibodies with a focus on inflammatory diseases and cancer. The scientists and developers at AnaptysBio use the latest technologies to identify and develop potential candidates in a rapid, precise, and cost-effective approach. AnaptysBio takes a differentiated approach to antibody identification and specializes in the development of biological therapeutics. AnaptysBio has a wide range of products, including Atrmab, ANB020, ANB019, and Etokimab. Atrmab is a nasal administration antibody product developed to treat allergic diseases such as hay fever. ANB020 is an antibody specifically targeting the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn's disease. On the other hand, the antibody ANB019 is being developed as a therapy option for both Generalized Pustular Psoriasis (GPP) and Palmoplantar Pustular Psoriasis (PPP). Etokimab, on the other hand, aims to treat tessin and chronic pruritus. This is a non-specific skin disease characterized by constant itching and tingling. By developing innovative therapies, AnaptysBio is able to achieve significant advancements in the field of biological medicines. These therapeutics will help improve the lives of patients in various stages of the disease. AnaptysBio benefits from serving a small but rapidly growing niche in the industry. There is a high demand for specialized biological medicines, as these medicines are often more effective and better tolerated than traditional medicines and are therefore preferred by many doctors. AnaptysBio finances its business activities through investment capital and strategic partnerships with large pharmaceutical companies. In the early stages of biological therapeutic development, AnaptysBio plays an important role by conducting proof-of-concept studies and demonstrating the potential of new therapeutics. Once the therapeutics move into clinical phases, pharmaceutical companies seek collaborations to conduct joint clinical trials and enter the market. Overall, AnaptysBio is a successful biotech company that is capable of revolutionizing therapy approaches for inflammatory and cancerous diseases. Through collaboration with large pharmaceutical companies and the development of innovative products, AnaptysBio is in a strong position to achieve further growth and success.

What is the AnaptysBio dividend?

AnaptysBio pays a dividend of 0 USD distributed over payouts per year.

How often does AnaptysBio pay dividends?

The dividend cannot currently be calculated for AnaptysBio or the company does not pay out a dividend.

What is the AnaptysBio ISIN?

The ISIN of AnaptysBio is US0327241065.

What is the AnaptysBio WKN?

The WKN of AnaptysBio is A2AJ8C.

What is the AnaptysBio ticker?

The ticker of AnaptysBio is ANAB.

How much dividend does AnaptysBio pay?

Over the past 12 months, AnaptysBio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AnaptysBio is expected to pay a dividend of 0 USD.

What is the dividend yield of AnaptysBio?

The current dividend yield of AnaptysBio is .

When does AnaptysBio pay dividends?

AnaptysBio pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of AnaptysBio?

AnaptysBio paid dividends every year for the past 0 years.

What is the dividend of AnaptysBio?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is AnaptysBio located?

AnaptysBio is assigned to the 'Health' sector.

Wann musste ich die Aktien von AnaptysBio kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of AnaptysBio from 8/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/26/2024.

When did AnaptysBio pay the last dividend?

The last dividend was paid out on 8/26/2024.

What was the dividend of AnaptysBio in the year 2023?

In the year 2023, AnaptysBio distributed 0 USD as dividends.

In which currency does AnaptysBio pay out the dividend?

The dividends of AnaptysBio are distributed in USD.

All fundamentals about AnaptysBio

Our stock analysis for AnaptysBio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AnaptysBio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.